Hospital
Holy Rosary Healthcare
Holy Rosary Healthcare was paid $567K by Medicaid between Jan 2018 and Dec 2024, across 130 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoHOLY ROSARY HEALTHCARE
MILES CITY, MT 59301
MILES CITY, MT 59301
33aNPI1396074548assigned 12/17/2009
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$567K
24GClaims178,094
24DCodes billed130
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Medicare Defined Swing Bed Hospital Unit providers in Montana
Rank by total paid#3 of 8
Median peer was paid$14K
This provider vs. median39×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,811 | $95K | |
| 2019 | 22,405 | $85K | |
| 2020 | 20,410 | $77K | |
| 2021 | 25,340 | $69K | |
| 2022 | 28,812 | $103K | |
| 2023 | 32,140 | $78K | |
| 2024incomplete | 24,176 | $60K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 7,128 | 5,879 | $145K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 4,859 | 3,686 | $71K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 9.7% | 5,347 | 1,539 | $55K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.3% | 3,550 | 2,524 | $47K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.9% | 10,567 | 3,006 | $39K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 6.5% | 2,036 | 745 | $37K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 576 | 529 | $17K |
| G0378 | Hospital observation service, per hour | 2.8% | 1,320 | 805 | $16K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 353 | 304 | $10K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 1,002 | 946 | $10K |
| 80053 | Comprehensive metabolic panel | 1.5% | 10,569 | 8,456 | $9K |
| J3490 | Unclassified drugs | 1.3% | 19,326 | 4,550 | $8K |
118 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 11,985 | $7K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 1,754 | $7K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 721 | $6K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.0% | 672 | $6K |
| 97161 | <1% | 1,033 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,115 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,004 | $5K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,329 | $4K |
| 80306 | <1% | 1,477 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,326 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,685 | $4K |
| 81001 | <1% | 5,854 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,520 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 610 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,149 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,319 | $2K |
| 83690 | <1% | 1,840 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,002 | $2K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 95 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,773 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,308 | $2K |
| 87631 | <1% | 48 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,961 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,322 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,772 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,893 | $1K |
| G0512 | Rural health clinic or federally qualified health center (rhc/fqhc) only, psychiatric collaborative care model (psychiatric cocm), 60 minutes or more of clinical staff time for psychiatric cocm services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm) and including services furnished by a behavioral health care manager and consultation with a psychiatric consultant, per calendar month | <1% | 152 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,172 | $982.74 |
| 87400 | <1% | 283 | $922.44 | |
| 81025 | <1% | 1,130 | $870.22 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 55 | $805.43 |
| 84484 | <1% | 2,302 | $759.87 | |
| 86140 | <1% | 733 | $704.55 | |
| 83605 | <1% | 1,266 | $673.18 | |
| 83880 | <1% | 251 | $576.66 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,166 | $516.66 |
| 87088 | <1% | 899 | $501.94 | |
| 83735 | <1% | 1,563 | $498.73 | |
| 80061 | Lipid panel | <1% | 1,925 | $496.30 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 520 | $475.42 |
| 94760 | <1% | 78 | $406.00 | |
| 87186 | <1% | 643 | $398.24 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 60 | $380.73 |
| 73610 | <1% | 29 | $362.61 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 181 | $346.35 |
| J2704 | Injection, propofol, 10 mg | <1% | 763 | $311.38 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 234 | $295.24 |
| 80050 | General health panel | <1% | 1,273 | $292.68 |
| 85610 | <1% | 982 | $284.65 | |
| 97165 | <1% | 27 | $276.86 | |
| 87040 | <1% | 485 | $223.38 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,925 | $214.33 |
| 96376 | <1% | 239 | $175.50 | |
| 90686 | <1% | 40 | $175.00 | |
| 73630 | <1% | 30 | $168.62 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,964 | $168.11 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 123 | $161.41 |
| 94762 | <1% | 37 | $145.43 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 99 | $143.93 |
| 87070 | <1% | 75 | $119.47 | |
| 87077 | <1% | 179 | $117.58 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,659 | $116.79 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 667 | $94.48 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 250 | $91.73 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 36 | $88.83 |
| 85027 | <1% | 323 | $87.42 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,302 | $83.35 |
| 85730 | <1% | 43 | $82.57 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 300 | $75.55 |
| 84703 | <1% | 98 | $69.74 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 484 | $49.41 |
| 73130 | <1% | 14 | $45.04 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 377 | $44.48 |
| 82962 | <1% | 839 | $32.15 | |
| 87081 | <1% | 12 | $26.85 | |
| 83550 | <1% | 25 | $11.71 | |
| 83540 | <1% | 85 | $8.67 | |
| 82947 | <1% | 930 | $5.31 | |
| 85652 | <1% | 138 | $3.62 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 4,921 | $0.00 |
| A9270 | Non-covered item or service | 0% | 996 | $0.00 |
| 84478 | 0% | 13 | $0.00 | |
| 86850 | 0% | 32 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 126 | $0.00 |
| 85379 | 0% | 20 | $0.00 | |
| 85651 | 0% | 77 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 80 | $0.00 |
| 99234 | 0% | 73 | $0.00 | |
| Q3014 | Telehealth originating site facility fee | 0% | 15 | $0.00 |
| 82043 | 0% | 12 | $0.00 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | 0% | 26 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 20 | $0.00 |
| 0352U | 0% | 12 | $0.00 | |
| 86901 | 0% | 42 | $0.00 | |
| 99459 | 0% | 13 | $0.00 | |
| 99441 | 0% | 14 | $0.00 | |
| 82607 | 0% | 13 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 20 | $0.00 |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 0% | 16 | $0.00 |
| 0011A | 0% | 18 | $0.00 | |
| 97162 | 0% | 12 | $0.00 | |
| 87205 | 0% | 13 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 95 | $0.00 |
| 59025 | Fetal non-stress test | 0% | 137 | $0.00 |
| 87210 | 0% | 90 | $0.00 | |
| 82570 | 0% | 97 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 82 | $0.00 |
| 87420 | 0% | 12 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 80 | $0.00 |
| 86900 | 0% | 43 | $0.00 | |
| 84100 | 0% | 99 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 17 | $0.00 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 0% | 12 | $0.00 |
| 82465 | 0% | 12 | $0.00 | |
| 84439 | 0% | 25 | $0.00 | |
| 72100 | 0% | 16 | $0.00 | |
| 73562 | 0% | 16 | $0.00 | |
| 83718 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPALAGI, PAMELA (VP FINANCE)
Parent organizationSISTERS OF CHARITY OF LEAVENWORTH HEALTH SYSTEM, INC
| Provider | Location | Paid |
|---|---|---|
| SCL Health Montana | Billings, MT | $13.69M |
| Holy Rosary Healthcare | Miles City, MT | $200K |
| Holy Rosary Healthcare - Case Management | Miles City, MT | $97K |
| ST. James Healthcare | Butte, MT | $48K |
| Holy Rosary Healthcare | Miles City, MT | $330.93 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.